Chemo plus anti-PD-1 therapy and sitagliptin before surgery for locally advanced pMMR colorectal cancer
Official title: A Phase Ib/II Study of Neoadjuvant Chemotherapy Combined With Anti-PD-1 Antibody and DPP4 Inhibitor Sitagliptin for Locally Advanced pMMR Colorectal Cancer
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07365592 · Data updated 2026-11-12
This trial tests whether adding sitagliptin and an anti‑PD‑1 antibody to standard pre‑surgery chemotherapy can increase tumor shrinkage in adults with locally advanced pMMR colorectal cancer.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 138 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | April 9, 2026 |
| Main results expected | December 1, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07365592 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 18–75 years old with pathologically confirmed colorectal adenocarcinoma staged T3‑4aNany or TanyN1‑2 without distant metastasis, confirmed pMMR by immunohistochemistry, and who are fit for chemotherapy with life expectancy of at least one year.
✕Probably not a fit
Patients with distant metastasis, multifocal colorectal cancer, major uncontrolled organ disease, inability to receive chemotherapy, or those who refuse participation are unlikely to benefit from this neoadjuvant combination.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a combined phase Ib/II trial testing the safety and activity of sitagliptin added to XELOX chemotherapy and an anti‑PD‑1 monoclonal antibody as neoadjuvant treatment for proficient mismatch repair (pMMR) colorectal cancer. The phase Ib portion is a single‑center 3+3 dose‑escalation study to determine the recommended phase II dose of sitagliptin and to characterize safety and immune changes in the tumor microenvironment. The phase II portion is a prospective, randomized controlled superiority trial conducted across centers to compare the combination regimen with the current standard approach for locally advanced disease. Primary aims include safety, degree of tumor regression prior to surgery, and exploratory immune biomarkers associated with response.
Why it matters
Potential benefit: If successful, the combination could increase the degree of tumor regression before surgery and potentially reduce recurrence for patients with locally advanced pMMR colorectal cancer.
How similar studies have gone: Single‑agent PD‑1 therapies have limited activity in pMMR CRC, combination chemo‑immunotherapy approaches have shown only modest and variable signals in this population, and adding a DPP‑4 inhibitor like sitagliptin to this regimen is a relatively novel strategy with limited prior clinical evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically diagnosed colorectal adenocarcinoma * Age ≥18 years old and ≤75 years old * MRI/CT stage T3-4aNany and TanyN1-2, without distant metastasis * Life expectancy of 1 year The above * Informed consent, no contraindications to chemotherapy exist * pMMR diagnosed by IHC Exclusion Criteria: * Refused to participate in this study * Multifocal colorectal cancer * Past history of malignant tumors, except for basal cell carcinoma/papillary thyroid carcinoma/various types of carcinoma in situ * Unable to receive chemotherapy , such as but not limited to bone marrow suppression, etc * Major organ diseases (such as but not limited to COPD, coronary heart disease and renal insufficiency, etc.) acute attack and or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia and myocarditis, etc.), * ASA score\> 3 * Mental disorder or illiteracy or language and communication barriers cannot understand the research plan * Colorectal tumor has obstruction or high risk of obstruction and or there is bleeding and/or perforation * Peripheral sensory nerve disorder, unable to receive oxaliplatin chemotherapy * Lateral pelvic lymph node metastasis (mainly supplied by internal iliac artery) * Pregnancy or breastfeeding * Unable to accept MRI examination * Consecutive use of glucocorticoids for more than 3 days within 1 month before signing the consent form * Diabetes or impaired glucose tolerance who may require drug intervention * Other scenarios deemed inappropriate by the investigators
Where it's running
-
Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Jun Li, MD
- Email: 2307016@zju.edu.cn
- Phone: +86 13777878061
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.